File downloaded on 2026-11-16
Source URL: https://medicines.health.europa.eu/veterinary/en/600000043296

MILBEMAX 12.5 MG/125 MG CHEWABLE TABLETS FOR DOGS

Authorised

- Milbemycin oxime
- Praziquantel

Product identification

Medicine name:
MILBEMAX 12.5 MG/125 MG CHEWABLE TABLETS FOR DOGS

Active substance:
Milbemycin oxime

Praziquantel

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Milbemycin oxime
12.50 milligram(s) / 1.00 Tablet

Praziquantel

125.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP54AB51

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Denmark

Available in:
Denmark

Package description:
Available only in French
Available only in French
Available only in French
Available only in French
Available only in French
Available only in French
Available only in French

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Elanco GmbH

Marketing authorisation date:
9/11/2009

Manufacturing sites for batch release:
Elanco France S.A.S.

Responsible authority:
Danish Medicines Agency

Authorisation number:
45452

Date of authorisation status change:
9/11/2009

Reference member state:
France

Procedure number:
FR/V/0135/006

Concerned member states:
Austria Belgium Cyprus Czechia Denmark Finland Germany Greece Hungary Ireland Italy Luxembourg Netherlands Norway Poland Portugal Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents